Differences in HIV-1 viral loads between male and female antiretroviral-untreated mexican patients

Archives of Medical Research

Volumn 44, Issue 4, 2013, Pages 296-301

  Ballesteros Zebadúa, Paola ^a,b   Villarreal, Carlos ^a   Cocho, Germinal ^a   Huerta, Leonor ^a   Estrada, José Luis ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b SECRETARÍA DE SALUD   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Age factors; Antiretroviral therapy; CD4+ T cell count; HIV 1; Sex associated factors; Viral load

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; RANK SUM TEST; RETROSPECTIVE STUDY; SEX DIFFERENCE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; VIRAL LOAD;

EID: 84879714114     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.04.003     Document Type: Article

References (38)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2012;2012. Available from:. http://www.unaids.org/en/resources/campaigns/20121120_globalreport2012/globalreport/.
2. Registro Nacional de Casos de SIDA (CENSIDA) SSA SS/DGE. Panorama epidemiológico 2011; 2011. Available from:. http://www.censida.salud.gob.mx/descargas/2011/casos_acumulados_marzo2011.pdf.
3. Holodniy M. HIV-1 load quantitation: a 17-year perspective. J Infect Dis 2006, 194:S38-S44.
4. Department of Health and Human Services (U.S.). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents;2011.
5. Haase A.T., Henry K., Zupancic M., et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996, 274:985-989.
6. + T-cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999, 17:625-656.
7. Gilad J., Walfisch A., Borer A., et al. Gender differences and sex-specific manifestations associated with human immunodeficiency virus infection in women. Eur J Obstet Gynecol Reprod Biol 2003, 109:199-205.
8. Gandhi M., Bacchetti P., Miotti P., et al. Does patient sex affect human immunodeficiency virus levels?. Clin Infect Dis 2002, 35:313-322.
9. Farzadegan H., Hoover D.R., Astemborski J., et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998, 352:1510-1514.
10. Napravnik S., Poole C., Thomas J.C., et al. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002, 31:11-19.
11. Sterling T.R., Vlahov D., Astemborski J., et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001, 344:720-725.
12. Anastos K., Gange S.J., Lau B., et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000, 24:218-226.
13. Donnelly C.A., Bartley L.M., Ghani A.C., et al. Gender difference in HIV-1 RNA viral loads. HIV Med 2005, 6:170-178.
14. Smith P.R., Sarner L., Murphy M., et al. Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1 infected individuals. J Clin Virol 2003, 26:101-107.
15. Katzenstein D.A., Hammer S.M., Hughes M.D., et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996, 335:1091-1098.
16. Moore R.D., Cheever L., Keruly J.C., et al. Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet 1999, 353:463-464.
17. Bush C.E., Donovan R.M., Markowitz N., et al. Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. J Clin Microbiol 1996, 34:970-972.
18. Collazos J., Asensi V., Cartón J.A. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007, 21:835-843.
19. Moore A.L., Kirk O., Johnson A.M., et al. EuroSIDA group. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003, 32:452-461.
20. Floridia M., Giuliano M., Palmisano L., et al. Gender differences in the treatment of HIV infection. Pharmacol Res 2008, 58:173-182.
21. Soto-Ramírez L.E., Quiroz L.A., Hernández-Tepichín G., et al. Guía de manejo antirretroviral de las personas con VIH 2008, Secretaría de Salud, Distrito Federal (Mexico). 4th ed.
22. Forbi J.C., Agwale S.M. Inverted CD4+/CD8+ ratio associated with AIDS event and death in HIV-1 infected individuals in Nasarawa State, Nigeria. Tanzan J Health Res 2009, 11:144-148.
23. Krantz E.M., Hullsiek K.H., Okulicz J.F., et al. Elevated CD8 counts during HAART are associated with HIV virologic treatment failure. J Acquir Immune Defic Syndr 2011, 57:396-403.
24. Ray K., Gupta S.M., Bala M., et al. CD4/CD8 lymphocyte counts in healthy, HIV-positive individuals & AIDS patients. Indian J Med Res 2006, 124:319-330.
25. Greenblatt R.M., Ameli N., Grant R.M., et al. Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis 2000, 181:82-90.
26. Shanker G., Sorci-Thomas M., Adams M.R. Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells. Lymphokine Cytokine Res 1994, 13:377-382.
27. Verthelyi D. Female's heightened immune status: estrogen, T-cells, and inducible nitric oxide synthase in the balance. Endocrinology 2006, 147:659-661.
28. Iñigo Riesgo C.A., Torres Gómez L.G., Lofte Navarro C.A., et al. Cardiovascular risk factors in climacteric. Ginecol Obstet Mex 2009, 77:535-543.
29. Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys?. AIDS 2002, 16:97-104. European Collaborative Study.
30. Smith-Franklin B.A., Keele B.F., Tew J.G., et al. Follicular dendritic cells and the persistence of HIV infectivity: the role of antibodies and Fc gamma receptors. J Immunol 2002, 168:2408-2414.
31. Keele B.F., Tazi L., Gartner S., et al. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol 2008, 82:5548-5561.
32. Meier A., Chang J.J., Chan E.S., et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009, 15:955-959.
33. Biancotto A., Grivel J.C., Iglehart S.J., et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007, 109:4272-4279.
34. Gilbert P., Wang M., Wrin T., et al. Magnitude and breadth ofa nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010, 202:595-605.
35. Gilbert P.B., Peterson M.L., Follmann D., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005, 191:666-677.
36. Zeng M., Smith A.J., Wietgrefe S.W., et al. Cumulative mechanisms oflymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011, 121:998-1008.
37. Fauci A.S. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993, 262:1011-1018.
38. Kaufmann G.R., Perrin L., Pantaleo G., et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003, 163:2187-2195.